A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer
- 15 November 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (22) , 10639-10642
- https://doi.org/10.1158/0008-5472.can-06-2522
Abstract
Tumor antigens are of interest as diagnostic and prognostic markers and potential therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma (PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic marker for clinical outcome. It has been shown recently that PRAME functions as a repressor of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing interest in tumor antigens as targets for therapy. (Cancer Res 2006; 66(22): 10639-42)Keywords
This publication has 25 references indexed in Scilit:
- Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approachesBlood, 2006
- Detection and Functional Analysis of CD8+ T Cells Specific for PRAME: a Target for T-Cell TherapyClinical Cancer Research, 2006
- Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid LeukemiaClinical Cancer Research, 2006
- Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidineCancer Research, 2004
- Gene expression profiling of pediatric acute myelogenous leukemiaBlood, 2004
- Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating markerBritish Journal of Haematology, 2004
- mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapiesInternational Journal of Cancer, 2003
- Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genesOncogene, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory ReceptorImmunity, 1997